Pharmacological Profile of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy: A Japanese Experience

References

• Mendell JR, Shilling C, Leslie ND, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol. 2012;71(3):304–313. doi:10.1002/ana.2352822451200
   PubMed Web of Science ®Google Scholar
• Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919–928. doi:10.1016/0092-8674(87)90579-43319190
   PubMed Web of Science ®Google Scholar
• Zubrzycka-Gaarn EE, Bulman DE, Karpati G, et al. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature. 1988;333(6172):466–469. doi:10.1038/333466a03287171
   PubMed Web of Science ®Google Scholar
• Manzur AY, Kinali M, Muntoni F. Update on the management of Duchenne muscular dystrophy. Arch Dis Child. 2008;93(11):986–990. doi:10.1136/adc.2007.11814118667451
   PubMed Web of Science ®Google Scholar
• Mah J. Current and emerging treatment strategies for Duchenne muscular dystrophy. Neuropsychiatr Dis Treat. 2016;12:1795–1807. doi:10.2147/NDT.S9387327524897
   PubMed Web of Science ®Google Scholar
• Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50(3):509–517. doi:10.1016/0092-8674(87)90504-63607877
   PubMed Web of Science ®Google Scholar
• van Deutekom JCT, van Ommen G-JB. Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet. 2003;4(10):774–783. doi:10.1038/nrg118014526374
   PubMed Web of Science ®Google Scholar
• Juan-Mateu J, Gonzalez-Quereda L, Rodriguez MJ, et al. DMD mutations in 576 dystrophinopathy families: a step forward in genotype-phenotype correlations. Ervasti JM, ed. PLoS One. 2015;10(8):e0135189. doi:10.1371/journal.pone.013518926284620
   PubMed Web of Science ®Google Scholar
• Oudet C, Hanauer A, Clemens P, Caskey T, Mandel J-L. Two hot spots of recombination in the DMD gene correlate with the deletion prone regions. Hum Mol Genet. 1992;1(8):599–603. doi:10.1093/hmg/1.8.5991363782
   PubMed Web of Science ®Google Scholar
• Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003;2(12):731–740. doi:10.1016/S1474-4422(03)00585-414636778
   PubMed Web of Science ®Google Scholar
• Werneck LC, Lorenzoni PJ, Ducci RD-P, Fustes OH, Kay CSK, Scola RH. Duchenne muscular dystrophy: an historical treatment review. Arq Neuropsiquiatr. 2019;77(8):579–589. doi:10.1590/0004-282x2019008831508685
   PubMed Web of Science ®Google Scholar
• Rutter MM, Collins J, Rose SR, et al. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord. 2012;22(12):1046–1056. doi:10.1016/j.nmd.2012.07.00922967789
   PubMed Web of Science ®Google Scholar
• Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet. 1974;304(7894):1409–1412. doi:10.1016/S0140-6736(74)90071-3
   Google Scholar
• Wood CL, Straub V, Guglieri M, Bushby K, Cheetham T. Short stature and pubertal delay in Duchenne muscular dystrophy. Arch Dis Child. 2016;101(1):101–106. doi:10.1136/archdischild-2015-30865426141541
   PubMed Web of Science ®Google Scholar
• Echevarría L, Aupy P, Goyenvalle A. Exon-skipping advances for Duchenne muscular dystrophy. Hum Mol Genet. 2018;27(R2):R163–R172. doi:10.1093/hmg/ddy17129771317
   PubMed Web of Science ®Google Scholar
• Sheikh O, Yokota T. Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies. Expert Opin Investig Drugs. 2021;30(2):167–176. doi:10.1080/13543784.2021.1868434
   PubMed Web of Science ®Google Scholar
• Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. 2019;15(7):373–386. doi:10.1038/s41582-019-0203-331147635
   PubMed Web of Science ®Google Scholar
• Aartsma-Rus A, Corey DR. The 10th oligonucleotide therapy approved: golodirsen for Duchenne muscular dystrophy. Nucleic Acid Ther. 2020;30(2):67–70. doi:10.1089/nat.2020.084532043902
   PubMed Web of Science ®Google Scholar
• Casimersen (Amondys 45) for Duchenne muscular dystrophy. Med Lett Drugs Ther. 2021;63(1627):e104–e105. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34181634. Accessed November 15, 2021.34181634
   PubMedGoogle Scholar
• Shirley M. Casimersen: first approval. Drugs. 2021;81(7):875–879. doi:10.1007/s40265-021-01512-233861387
   PubMed Web of Science ®Google Scholar
• Roshmi RR, Yokota T. Viltolarsen for the treatment of Duchenne muscular dystrophy. Drugs Today. 2019;55(10):627. doi:10.1358/dot.2019.55.10.3045038
   PubMed Web of Science ®Google Scholar
• Dhillon S. Viltolarsen: first approval. Drugs. 2020;80(10):1027–1031. doi:10.1007/s40265-020-01339-332519222
   PubMed Web of Science ®Google Scholar
• Lim KR, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 2017;11:533–545. doi:10.2147/DDDT.S97635
   PubMed Web of Science ®Google Scholar
• Nan Y, Zhang Y-J. Antisense phosphorodiamidate morpholino oligomers as novel antiviral compounds. Front Microbiol. 2018;9. doi:10.3389/fmicb.2018.00750
   Web of Science ®Google Scholar
• Gao QQ, McNally EM. The dystrophin complex: structure, function, and implications for therapy. In: Comprehensive Physiology. Wiley; 2015:1223–1239. doi:10.1002/cphy.c140048
   Google Scholar
• Le Rumeur E. Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies. Bosn J Basic Med Sci. 2015;15(3). doi:10.17305/bjbms.2015.636
   Web of Science ®Google Scholar
• Yokota T, Lu Q, Partridge T, et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol. 2009;65(6):667–676. doi:10.1002/ana.2162719288467
   PubMed Web of Science ®Google Scholar
• Watanabe N, Nagata T, Satou Y, et al. NS-065/NCNP-01: an antisense oligonucleotide for potential treatment of exon 53 skipping in Duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2018;13:442–449. doi:10.1016/j.omtn.2018.09.01730388618
   PubMedGoogle Scholar
• Heo Y-A. Golodirsen: first approval. Drugs. 2020;80(3):329–333. doi:10.1007/s40265-020-01267-232026421
   PubMed Web of Science ®Google Scholar
• Viltolarsen. Am J Health Pharm. 2020;77(24):2032–2033. doi:10.1093/ajhp/zxaa324
   Google Scholar
• Komaki H, Takeshima Y, Matsumura T, et al. Viltolarsen in Japanese Duchenne muscular dystrophy patients: a Phase 1/2 study. Ann Clin Transl Neurol. 2020;7(12):2393–2408. doi:10.1002/acn3.5123533285037
   PubMed Web of Science ®Google Scholar
• Clemens PR, Rao VK, Connolly AM, et al. Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping. JAMA Neurol. 2020;77(8):982. doi:10.1001/jamaneurol.2020.126432453377
   PubMed Web of Science ®Google Scholar
• Komaki H, Nagata T, Saito T, et al. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. Sci Transl Med. 2018;10(437). doi:10.1126/scitranslmed.aan0713
   PubMed Web of Science ®Google Scholar
• The Cooperative International Neuromuscular Research Group (CINRG). Available from: https://cinrgresearch.org/duchenne-natural-history/. Accessed November 15, 2021.
   Google Scholar
• NS PHARMA’S VILTEPSOTM (viltolarsen) injection now FDA-approved in the U.S. for the treatment of Duchenne muscular dystrophy in patients amenable to exon 53 skipping therapy. NS Pharma News Release; 2020. Available from: https://www.nspharma.com/pdfs/Viltepso_Approval_Press_Release.pdf. Accessed November 15, 2021.
   Google Scholar
• ClinicalTrials.gov Exploratory Study of NS-065/NCNP-01 in DMD. Available from: https://clinicaltrials.gov/ct2/show/NCT02081625. Accessed November 15, 2021.
   Google Scholar
• ClinicalTrials.gov safety and dose finding study of NS-065/NCNP-01 in boys with Duchenne Muscular Dystrophy (DMD). Available from: https://clinicaltrials.gov/ct2/show/NCT02740972. Accessed November 15, 2021.
   Google Scholar
• ClinicalTrials.gov Study to assess the efficacy and safety of viltolarsen in ambulant boys with DMD (RACER53). Available from: https://clinicaltrials.gov/ct2/show/NCT04060199. Accessed November 15, 2021.
   Google Scholar
• ClinicalTrials.gov Extension Study of NS-065/NCNP-01 in boys with Duchenne Muscular Dystrophy (DMD). Available from: https://clinicaltrials.gov/ct2/show/NCT03167255. Accessed November 15, 2021.
   Google Scholar
• Matsuo M, Takeshima Y, Nishio H. Contributions of Japanese patients to development of antisense therapy for DMD. Brain Dev. 2016;38(1):4–9. doi:10.1016/j.braindev.2015.05.01426094594
   PubMed Web of Science ®Google Scholar
• Takeshima Y, Nishio H, Sakamoto H, Nakamura H, Matsuo M. Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. J Clin Invest. 1995;95(2):515–520. doi:10.1172/JCI1176937860733
   PubMed Web of Science ®Google Scholar
• Shiga N, Takeshima Y, Sakamoto H, et al. Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy. J Clin Invest. 1997;100(9):2204–2210. doi:10.1172/JCI1197579410897
   PubMed Web of Science ®Google Scholar
• Nakamura H, Kimura E, Mori-Yoshimura M, et al. Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy). Orphanet J Rare Dis. 2013;8(1):60. doi:10.1186/1750-1172-8-6023601510
   PubMed Web of Science ®Google Scholar
• Remudy. Available from: http://www.remudy.jp/news/2021/09/005992.html. Accessed November 15, 2021.
   Google Scholar
• Viltolarsen (viltepso) for Duchenne muscular dystrophy. Med Lett Drugs Ther. 2020;62(1609):167.33429411
   PubMed Web of Science ®Google Scholar
• Meyers TA, Townsend D. Cardiac pathophysiology and the future of cardiac therapies in Duchenne muscular dystrophy. Int J Mol Sci. 2019;20(17):4098. doi:10.3390/ijms20174098
   PubMed Web of Science ®Google Scholar